FoundationOne Fluid is a next-generation sequencing (NGS) pan-cancer companion diagnostic that profiles tumor DNA to identify treatment options across multiple cancer types. This evergreen explainer details its technical platform, clinical validity and utility, targeted therapy and immunotherapy implications, turnaround times, and limitations. It is designed to serve as a long-term reference for clinicians, pathologists, and patients seeking clarity on when and how this assay is used in precision oncology care.
Technology and design of FoundationOne Fluid
FoundationOne Fluid is a DNA-based pan-tumor (pan-cancer) next-generation sequencing assay that analyzes formalin-fixed, paraffin-embedded (FFPE) tumor tissue to identify alterations across hundreds of cancer-related genes. It is intended as a companion diagnostic to inform treatment decisions with targeted therapies and to report on potential response to immunotherapy where relevant. The test examines more than 300 genes for variants including substitutions, insertions, deletions, copy number changes, and selected rearrangements, while also reporting microsatellite instability (MSI) and tumor mutational burden (TMB) as part of its profiling output.
The assay is designed to support broad applicability across tumor types, reflecting an unbiased, genome-informed approach rather than gene selection tied to any single cancer. This pan-cancer methodology provides a single testing pathway that can remain relevant as treatment options expand. Its analytic performance has been validated using multiple sample types and sequencing depths to ensure reliable variant detection in clinical practice.
Key analytic performance metrics
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Assay type | DNA-based NGS pan-cancer panel | Product documentation (verified) |
| Genes profiled | Approximately 300+ genes | Publicly available specifications |
| Sample type | FFPE tumor tissue | Label and method papers |
| Reported TMB and MSI | Yes, included in results | Validation studies |
| Intended use | Companion diagnostic for therapy selection | Regulatory clearances |
Clinical indications and tumor-agnostic use
FoundationOne Fluid is indicated as an aid in treatment selection for patients with metastatic solid tumors whose cancers harbor alterations associated with targeted therapies approved by the FDA or other relevant regulatory authorities in specific jurisdictions. It also reports on features relevant to immunotherapy, such as MSI status and TMB, which may inform consideration of immune checkpoint inhibitors in certain tumor types. Because it is a pan-cancer test, it can be applied regardless of primary site when comprehensive profiling is clinically relevant.
The tumor-agnostic paradigm relies on identifying actionable alterations irrespective of histology, aligning therapy selection with molecular findings rather than anatomy alone. This approach is particularly meaningful in rare, refractory, or poorly characterized tumors where standard panels may not capture treatment opportunities. Guidance from oncology societies and regulators helps define when comprehensive profiling is appropriate and how results should be integrated into multidisciplinary discussions.
Tumor-agnostic testing scenarios (examples)
- Metastatic tumors of unknown primary origin where treatment options are limited.
- Rare or pediatric cancers with few standard targeted therapy options.
- Cases where prior targeted testing has been negative or incomplete.
- Situations where immunotherapy candidacy needs evaluation via MSI or TMB.
Targeted therapy and immunotherapy implications
The primary clinical value of FoundationOne Fluid lies in identifying alterations that match approved targeted treatments, including tyrosine kinase inhibitors, antibody-drug conjugates, and other mechanism-specific agents. For each actionable variant, the report provides evidence-level associations and, where available, therapy options that have been approved or are under investigation. This allows clinicians to match tumor molecular profiles with precision therapies in a structured way.
In parallel, the assay reports on features relevant to immunotherapy. High microsatellite instability (MSI-H) or elevated tumor mutational burden (TMB-H) may suggest increased likelihood of response to PD-1/PD-L1 inhibitors in certain tumor types, although these biomarkers are not universally predictive. Results should always be interpreted in the context of tumor type, stage, prior therapies, and current evidence to avoid overgeneralization across cancer indications.
Targeted versus immunotherapy reporting
| Feature | Targeted therapy relevance | Immunotherapy relevance |
|---|---|---|
| Actionable gene fusions | High (guides targeted agent selection) | Low direct impact |
| MSI status | Low to moderate | High in selected tumor types |
| TMB level | Variable, context-dependent | Moderate; used with other factors |
| Known resistance alterations | Yes, informs second-line options | Limited role |
Clinical validity, utility, and performance considerations
FoundationOne Fluid demonstrates robust analytical performance with low assay failure rates and high coverage of target regions in well-processed FFPE samples. Clinical validity is supported by analytical sensitivity, specificity, and comparisons with other validated NGS platforms when performed in credentialed laboratories. Clinical utility depends on the availability of matched therapies, the biological relevance of detected alterations, and how results are integrated into clinical decision-making pathways.
Healthcare systems evaluate such assays not only on technical metrics but also on turnaround time, cost-effectiveness, and impact on patient outcomes. Appropriate patient selection and clear documentation of tumor type, stage, and prior therapies help ensure that results are actionable. Multidisciplinary review remains essential to align molecular findings with the broader treatment strategy.
Performance highlights (general reference)
| Metric | Estimate or Range | Context |
|---|---|---|
| Analytical sensitivity | Typically 1–5% variant allele frequency | Laboratory-verified detection limit |
| Assay coverage | Comprehensive gene panel with high targeted coverage | Uniform coverage across genes |
| Turnaround time | Several business days from receipt | Lab-specific timelines may vary |
| Sample adequacy | Sufficient tumor content required | FFPE quality influences results |
Limitations, challenges, and practical interpretation
No genomic assay captures all clinically relevant alterations, and FoundationOne Fluid has defined limitations. These include dependency on tumor content and DNA quality, challenges in detecting certain complex rearrangements or low-frequency clones, and the potential for variants of uncertain significance that require further study. Not all detected alterations will have an available targeted therapy, and some may reveal incidental findings unrelated to the primary cancer that need separate management considerations.
Clinicians should pair testing with expert interpretation, considering tumor type, stage, comorbidities, and prior treatments. Coordination with specialized pathology services and access to molecular tumor boards can enhance result interpretation. Understanding both what the test can and cannot provide reduces misapplication and supports more precise treatment planning.
When and how to use FoundationOne Fluid in care pathways
FoundationOne Fluid is best considered at the point when comprehensive genomic profiling is needed to guide advanced solid tumor management, particularly after standard options are exhausted or when tumor-agnostic treatment strategies are being explored. Early involvement of molecular diagnostics and multidisciplinary teams helps ensure that eligible patients are offered appropriate testing and that results lead to timely treatment decisions.
Integration into care pathways should include clear documentation, pre- and post-test counseling, and alignment with institutional formularies and evidence policies. Re-testing may be considered if new treatment options emerge or if prior material is limited, and coordination with trial networks can connect patients to experimental approaches based on molecular findings.
Key considerations for clinicians
- Confirm tumor type, stage, and prior therapies before ordering.
- Ensure adequate tumor tissue and proper handling for FFPE processing.
- Use evidence-based guidelines and institutional panels to interpret actionable results.
- Engage pathology and molecular experts for complex or ambiguous findings.
- Discuss limitations, including variants of uncertain significance, with the treatment team and patient.